History repeats itself: The acquisition method and nonrecurring charges
Nina T. Dorata
Accounting forum, 2009, vol. 33, issue 1, 11-26
Abstract:
The Financial Accounting Standards Board issued Statement No. 141 (R) that replaces Statement of Financial Accounting Standard No. 141, Business Combinations. The new standard mandates use of the acquisition method, which requires expense treatment for acquisition-related transaction costs. Expense treatment is a departure from purchase accounting procedures, but is consistent with past guidance of Accounting Principles Board Opinion No. 16 for the pooling-of-interests method. Restoration of historical and controversial accounting procedures resurrects past outcomes. This study utilizes econometric techniques to predict outcomes of the acquisition method. Evidence indicates that expensing acquisition-related costs may improve transparent reporting. The results, based on 638 business combinations from 1994 through 1998, support the expectation that expense treatment for acquisition-related costs increases the likelihood that these costs appear more frequently and are greater in magnitude.
Keywords: Business combinations; Nonrecurring charges; Acquisition accounting method; Logistic; Tobit; Regressions (search for similar items in EconPapers)
Date: 2009
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0155998208000458
Full text for ScienceDirect subscribers only
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:eee:accfor:v:33:y:2009:i:1:p:11-26
DOI: 10.1016/j.accfor.2008.07.004
Access Statistics for this article
Accounting forum is currently edited by Glen Lehman
More articles in Accounting forum from Elsevier
Bibliographic data for series maintained by Catherine Liu ().